Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers

<p>Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that its cancer-targeting immunotherapy antibody candidate has demonstrated effective tumor reduction against an aggressive subset of Non-Small […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ocean-biomedical-announces-newly-published-findings-demonstrating-ability-to-restore-treatment-sensitivity-to-astrazenecas-leading-lung-cancer-drug-after-resistance-has-formed-and-enhan/">Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>